Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

No New MACE, Zero Late Stent Thrombosis - Company Also Provides Clinical Program Update and Will Host Webcast Mon.,

Oct. 22 at 7:00 a.m. ET -

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I and CUSTOM II single-arm prospective studies evaluating the safety and efficacy of its Custom NX(R) drug-eluting stent system in patients with coronary artery disease.

At one-year CUSTOM II clinical follow-up and at two-year CUSTOM I clinical follow-up, no new major adverse cardiac events (MACE) were reported. The incidence of late stent thrombosis for patients treated with Custom NX in both trials was zero percent.

"These long term results are exceptional. CUSTOM I and II are unlike any other early stage drug-eluting stent trial because of the lesion length and complexity of the patients treated in these trials," said Professor Eberhard Grube, M.D., chief of cardiology at the HELIOS Heart Center in Siegburg, Germany, and Principal Investigator of CUSTOM I and CUSTOM II. Professor Grube presented CUSTOM I two-year results and CUSTOM II one-year results during a satellite symposium Sunday evening at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting.

Additionally, the company announced it recently filed its Investigational Device Exemption (IDE) to begin the CUSTOM IV pivotal trial and has now received questions back from the Food and Drug Administration (FDA). "Submission of our IDE was a significant milestone for the company and allows us to have clear discussions with the agency about the requirements necessary to gain approval to start the trial and continue our progress to bring Custom NX to physicians and patients," said Gregory D. Casciaro, President and CEO of XTENT. "We are quickly mobilizing to work with the FDA and as soon as we have spec
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...mab Program to be Discontinued and Headcount to be... its Portfolio Review; Zanolimumab Program to be ...r of Employees, COP...b A/S (OMX: GEN),announced today that it is discon... In addition, as a result of a portfolio review an...
(Date:10/8/2008)...gs Confirm Potency of Poly-ICR as Vaccine Adjuvant...nta Biopharmaceuticals,Corporation (TSX: NVN) toda... using its proprietary Toll-like Receptor 3 agonis...Vaccine Congress 2008 in Lyon, France.,Study resul...juvant,targeting the Toll-like Receptor 3 (TLR3) p...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...s, Oct. 7 /- The Texas Cardiac Arrhyt...r has been selected as one of,only a few sites in ...cal,trial for a new device to treat persistent atr..., training and research center specializing in hea...David,s Medical Center and,Texas Cardiovascular Co...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Park Dental Announces Separation From Its Administrative Service Provider 13335 1Park Dental Announces Separation From Its Administrative Service Provider 13335 2Park Dental Announces Separation From Its Administrative Service Provider 13335 3Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 1Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 1Pump It Up and Autism Society of America Launch Bounce for Autism 13331 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 3MSU research indicates testosterone could guard against eating disorders 13329 1MSU research indicates testosterone could guard against eating disorders 13329 2
...udy Showed Bioequivalence , LONDON, UK and ATLANTA...AQ:SKYE) and Sciele Pharma. Inc. (NASDAQ:SCRX) tod...cal trial programme,for the new formulation of Sul...tment of high blood pressure.,The study results sh...nt to Sciele,s currently marketed Sular. The new,...
...TA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - S...day announced positive data from,a statistical ana...atients with traumatic brain injury. In line with ...06, statistical results,confirmed that the primary...evels compared with baseline was met. Data also sh...
Other Medicine Technology:SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3
(Date:10/10/2008)...10 /PRNewswire-FirstCall/ -- Hologic, Inc.,(Nasdaq...upplier of premium,diagnostics, medical imaging sy...he healthcare needs of women, today announced plan...erating results on Tuesday, November 11,2008 afte...anagement will,host a conference call on Tuesday, ...
(Date:10/10/2008)... Topics range from bullying to incorporating PDAs ...us) October 10, 2008 -- Several pediatric experts ...presenting at the 2008 American Academy of Pediatr... from October 11 - 14 in Boston. Presenters and to...t, MD, MPH, will present "Promoting Smoke-Fre...
(Date:10/10/2008)...Calif., Oct. 10 /PRNewswire/ -- A senior citizen,s...ountains in a small,plane. The high-flying adventu.... The thrill came from a last-wish program through...nior Living, where Heden was a patient.,Called Go ...it has helped,many realize a special activity at t...
(Date:10/10/2008)...care partly to blame , , FRIDAY, Oct. 10...ciaries who have diabetes, being depressed was ass...ew study. , Publishing in the October issue o...archers from the University of Washington tracked ... years) who had diabetes and were enrolled in a di...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2Health News:Older Diabetics With Depression Face Higher Death Rate 2
... sex hormone levels during women’s menstrual cycle...d circuitry, an imaging study at the National Inst...e National Institutes of Health (NIH), has reveale...their circuitry was more active if they were in a ...
...erall cancer death rate in African Americans has c...te was 35 percent higher in African American men a...han in white men and women in the most recent time...ity among men has narrowed over the past 10 years ...
...outh heal more slowly in women and older adults, a...o reveals.// "While wounds to the skin heal more ...the opposite is true for healing of wounds inside ...rucha, head of periodontics at the UIC College of ...
...llion men in the United States over age 20 are aff...udy by researchers from the Johns Hopkins Bloomber...ile dysfunction was strongly linked with age, card...of physical activity. The findings also indicate...
Other Medicine News:Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Cancer Death Rates High in African-Americans 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2Health News:More Than 18 Million US Men Affected by ED 2
...medication, food, exercise, stress . . . Theyre al...health. Unfortunately, its difficult, and often ov...tion on a daily basis. Its even more difficult to ...formation to a care provider quickly so healthcare...
...es requires making decisions about insulin dosages... These decisions are guided by data from blood glu...the patterns that can be seen by you and your Heal...ganized and graphical formats. The FreeStyle CoPil...
...t Solid-State Three-Color Photocoagulator.,Retin...purchase over 3,000 Lumenis multi-color photocoagu...ractice, the Novus Varia integrates green, yellow,... single, compact system that supports your treatme...
...pe 14, 14A and 14C have been approved. The three r...modate the variations in the size of the individua... rings are designed to stabilize the capsule and h...e panel of U.S. ophthalmologists. For implatation...
Medicine Products: